Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193

Clin Infect Dis. 2019 Jan 7;68(2):334-337. doi: 10.1093/cid/ciy525.

Abstract

We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone-sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Communicable Diseases, Emerging / epidemiology*
  • Communicable Diseases, Emerging / microbiology*
  • Drug Resistance, Multiple, Bacterial*
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics*
  • Escherichia coli Infections / epidemiology
  • Escherichia coli Infections / microbiology*
  • Humans
  • Population Surveillance
  • Prevalence
  • Retrospective Studies
  • United States / epidemiology